Physician profile
Trung T Luong
NPI 1962611186
$3,892.21
in general payments reported to CMS, 2019-2025
26 companies · $1,223 in 2025
The $1,223 reported for 2025 was more than what 82% of Nephrology (Internal Medicine) providers received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $194 · 2020: $123 · 2021: $575 · 2022: $543 · 2023: $645 · 2024: $589 · 2025: $1,223.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,433 · Education: $24.61.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,432.54 |
| Education | $24.61 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $480.60 | 2021-2025 | Farxiga, Lokelma |
| Otsuka America Pharmaceutical, INC. | $470.36 | 2020-2025 | Jynarque |
| Vifor Pharma, INC. | $374.30 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $292.91 | 2020-2025 | Rayaldee |
| Horizon Therapeutics Plc | $262.80 | 2020-2023 | Krystexxa |
| Bayer Healthcare Pharmaceuticals INC. | $253.41 | 2022-2025 | |
| Scpharmaceuticals INC. | $230.33 | 2024-2025 | |
| Amgen INC. | $215.00 | 2022-2025 | Tavneos, Krystexxa |
| Mallinckrodt Hospital Products INC. | $192.99 | 2021-2025 | Acthar, Terlivaz |
| Novartis Pharmaceuticals Corporation | $156.85 | 2023-2025 | |
| Akebia Therapeutics INC | $126.96 | 2021-2025 | Vafseo, Auryxia |
| Travere Therapeutics, INC. | $122.62 | 2024-2025 | |
| Lilly USA, LLC | $97.75 | 2024-2025 | Jardiance |
| Calliditas Therapeutics US INC. | $89.50 | 2022-2025 | Tarpeyo |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $67.35 | 2019-2025 |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ardelyx, INC. | $60.44 | 2023-2025 | Ibsrela |
| Veloxis Pharmaceuticals, INC. | $60.05 | 2024-2025 | Envarsus |
| Glaxosmithkline, LLC. | $52.91 | 2023 | Benlysta |
| Cormedix INC. | $50.97 | 2025 | Defencath |
| Alexion Pharmaceuticals, INC. | $50.39 | 2022-2025 | Ultomiris |
| Novo Nordisk INC | $44.42 | 2025 | |
| Aurinia Pharma U.S., INC. | $43.54 | 2022-2023 | Lupkynis |
| Apellis Pharmaceuticals, INC. | $33.33 | 2025 | Empaveli |
| Ani Pharmaceuticals, INC. | $23.74 | 2023 | Purified Cortrophin Gel |
| Genzyme Corporation | $22.60 | 2023 | |
| Fresenius USA Marketing, INC. | $16.09 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Trung Luong listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.